The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation.
Open accessAbstract
The majority of human malignant glioma cells express Fas/APO-1 and are susceptible to Fas/APO-1 antibody-mediated apoptosis in vitro. The sensitivity of Fas/APO-1-positive glioma cell lines to Fas/APO-1 antibody-mediated killing correlates inversely with the constitutive expression of the antiapoptotic protooncogene bcl-2. Here we report that BCL-2 protein expression of human glial tumors in vivo correlates with malignant transformation in that BCL-2 immunoreactive glioma cells were more abundant in WHO grade III/IV gliomas than in grade I/II gliomas. Fas/APO-1 antibody-sensitive human glioma cell lines stably transfected with a murine bcl-2 cDNA acquired resistance to Fas/APO-1 antibody-mediated apoptosis. Forced expression of bcl-2 also attenuated TNF alpha-mediated cytotoxicity of glioma cell lines in the presence of actinomycin D and cycloheximide and conferred partial protection from irradiation and the cancer chemotherapy drugs, cisplatin and BCNU. Preexposure of the glioma cell lines to the cytokines, IFN gamma and TNF alpha, which sensitize for Fas/APO-1-dependent killing, partially overcame bcl-2-mediated rescue from apoptosis, suggesting that multimodality immunotherapy involving cytokines and Fas/APO-1 targeting might eventually provide a promising approach to the treatment of human malignant gliomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death.
Hockenbery, D. M., Zutter, M., Hickey, W., Nahm, M., & Korsmeyer, S. J. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.16.6961 · Cited by 1,252
Nuñez, G., London, L., Hockenbery, D., Alexander, M., McKearn, J. P., & Korsmeyer, S. J. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.144.9.3602 · Cited by 899
Cited by
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316
“On the mechanistic level, classical anti-apoptotic Bcl-2 family members (BAK, BAD, BID, BAX, BCL-X L , MCL-1) modulate apoptosis signaling by preserving mitochondrial membrane integrity and the release of cytochrome c, which effects the caspase cascade and the apoptotic program (for review, see Green and Kroemer 2004).”
BackgroundInfluentialDeath and anti-death: tumour resistance to apoptosis
Igney, F. H., & Krammer, P. H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc776 · Cited by 2,075
The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.
O'Connell, J., O'Sullivan, G. C., Collins, J. K., & Shanahan, F. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.3.1075 · Cited by 878
Harris, C. C. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.20.1442 · Cited by 680
Apoptosis and the Dilemma of Cancer Chemotherapy
Hannun, Y. A. (1997) · Blood · doi:10.1182/blood.v89.6.1845 · Cited by 605
Immune escape of tumors: apoptosis resistance and tumor counterattack
Igney, F. H., & Krammer, P. H. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.6.907 · Cited by 468
Rahaman, S. O., Harbor, P. C., Chernova, O., Barnett, G. H., Vogelbaum, M. A., & Haque, S. J. (2002) · Oncogene · doi:10.1038/sj.onc.1206047 · Cited by 377
“Studies have indicated that overexpression of the bcl-2 gene is sufficient to block Fas/FasL-mediated apoptosis in glioma cells (Weller et al., 1995).”
BackgroundMechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma
Sarkaria, J. N., Kitange, G. J., James, C. D., Plummer, R., Calvert, H., Weller, M., & Wick, W. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1719 · Cited by 373
Self-citationBcl–2 protects from lethal hepatic apoptosis induced by an ant–Fas antibody in mice
Lacronique, V., Mignon, A., Fabre, M., Viollet, B., Rouquet, N., Molina, T., Porteu, A., Henrion, A., Bouscary, D., Varlet, P., et al. (1996) · Nature Medicine · doi:10.1038/nm0196-80 · Cited by 369
Immune defects observed in patients with primary malignant brain tumors
Dix, A. R., Brooks, W. H., Roszman, T. L., & Morford, L. A. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00203-9 · Cited by 323
Schulz, J. B., Weller, M., & Klockgether, T. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-15-04696.1996 · Cited by 321
Self-citationLeist, M., & Nicotera, P. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6890 · Cited by 293
Targeting the Bcl-2 family for cancer therapy
Thomas, S., Quinn, B. A., Das, S. K., Dash, R., Emdad, L., Dasgupta, S., Wang, X.-Y., Dent, P., Reed, J. C., Pellecchia, M., et al. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.733001 · Cited by 277
Self-citationAnti-apoptotic Role of Telomerase in Pheochromocytoma Cells
Fu, W., Begley, J. G., Killen, M. W., & Mattson, M. P. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.11.7264 · Cited by 248
The Fas counterattack: Cancer as a site of immune privilege
O’Connell, J., Bennett, M. W., O’Sullivan, G. C., Collins, J. K., & Shanahan, F. (1999) · Immunology Today · doi:10.1016/s0167-5699(98)01382-6 · Cited by 232
Uckan, D. (1997) · Molecular Human Reproduction · doi:10.1093/molehr/3.8.655 · Cited by 206
Molecular determinants of glioma cell migration and invasion
Wild-Bode, C., Weller, M., & Wick, W. (2001) · Journal of Neurosurgery · doi:10.3171/jns.2001.94.6.0978 · Cited by 130
Self-citation
Metadata
- Authors
- Weller, M., Malipiero, U., Aguzzi, A., Reed, J. C., & Fontana, A.
- Venue
- Journal of Clinical Investigation
- Published
- 1995-06-01
- Volume
- 95
- Issue
- 6
- Pages
- 2633-2643
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2092589738
- Cited by
- 250
- References
- 2
- FWCI
- 8.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.